Enanta Pharmaceuticals Inc. diskutieren
Enanta Pharmaceuticals Inc.
WKN: A1T7BJ / Symbol: ENTA / Name: Enanta / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
10,60 €
0,95 %
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. They now have a $14.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $48.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at JMP Securities from $42.00 to $23.00. They now have an "outperform" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $28.00 to $27.00. They now have a "buy" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at JPMorgan Chase & Co. from $11.00 to $10.00. They now have an "underweight" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at Robert W. Baird from $26.00 to $20.00. They now have an "outperform" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $27.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at Westpark Capital. They set a "buy" rating and a $24.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target lowered by analysts at Evercore ISI from $20.00 to $12.00. They now have an "outperform" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) had its price target raised by analysts at Westpark Capital from $24.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for ENTA provided by MarketBeat
Neueste Beiträge
jamestaylor in Discuss Giga Media Ltd